http://orcid.org/0000-0002-9970-7641
Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Kyaw Hein, Nicholas Short, Elias Jabbour & Musa Yilmaz. (2022) Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia. Blood and Lymphatic Cancer: Targets and Therapy 12, pages 7-16.
Read now
Read now
Articles from other publishers (28)
Haipin Chen, Miner Gu, Juan Liang, Hua Song, Jingying Zhang, Weiqun Xu, Fenying Zhao, Diying Shen, Heping Shen, Chan Liao, Yongmin Tang & Xiaojun Xu. (2023) Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL. Nature Communications 14:1.
Crossref
Crossref
Alexandra E. Kovach & Brent L. Wood. (2023) Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis. Seminars in Diagnostic Pathology 40:6, pages 457-471.
Crossref
Crossref
Huirong Mai, Qin Li, Guobing Wang, Ying Wang, Shilin Liu, Xue Tang, Fen Chen, Guichi Zhou, Yi Liu, Tonghui Li, Lulu Wang, Chunyan Wang, Feiqiu Wen & Sixi Liu. (2022) Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia. Journal of Cancer Research and Clinical Oncology 149:7, pages 3259-3266.
Crossref
Crossref
Nouran Momen, Joseph Tario, Kai Fu & You-Wen Qian. (2023) Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease. Journal of Hematopathology 16:2, pages 85-94.
Crossref
Crossref
Anas Younes, John M. Burke, Bruce D. Cheson, Catherine S. Diefenbach, Silvia Ferrari, Uwe H. Hahn, Eliza A. Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina G. Nielsen, Gila Sellam & Jeff P. Sharman. (2023) Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma. Blood Advances 7:8, pages 1488-1495.
Crossref
Crossref
Donatella Talotta, Mohammad Almasri, Chiara Cosentino, Gianluca Gaidano & Riccardo Moia. (2023) Liquid biopsy in hematological malignancies: current and future applications. Frontiers in Oncology 13.
Crossref
Crossref
Shilpa Sampathi, Yelena Chernyavskaya, Meghan G. Haney, L. Henry Moore, Isabel A. Snyder, Anna H. Cox, Brittany L. Fuller, Tamara J. Taylor, Donglin Yan, Tom C. Badgett & Jessica S. Blackburn. (2022) Nanopore sequencing of clonal IGH rearrangements in cell-free DNA as a biomarker for acute lymphoblastic leukemia. Frontiers in Oncology 12.
Crossref
Crossref
Caner Saygin, Joseph Cannova, Wendy Stock & Lori Muffly. (2022) Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica 107:12, pages 2783-2793.
Crossref
Crossref
Eric Pierce, Benjamin Mautner, Joseph Mort, Anastassia Blewett, Amy Morris, Michael Keng & Firas El Chaer. (2022) MRD in ALL: Optimization and Innovations. Current Hematologic Malignancy Reports 17:4, pages 69-81.
Crossref
Crossref
Diede A. G. van Bladel, Wendy B. C. Stevens, Michiel van den Brand, Leonie I. Kroeze, Patricia J. T. A. Groenen, J. Han J. M. van Krieken, Konnie M. Hebeda & Blanca Scheijen. (2022) Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma. Cancers 14:13, pages 3222.
Crossref
Crossref
Mohammad O. Hussaini, Jaya SrivastavaLik Wee LeeTaiga Nishihori, Bijal D. Shah, Melissa Alsina, Javier Pinilla-Ibarz & Kenneth H. Shain. (2022) Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies. Archives of Pathology & Laboratory Medicine 146:4, pages 485-493.
Crossref
Crossref
Adam J. Olszewski, Anna D. ChorzalskaMax PetersenThomas A. Ollila, Adam Zayac, Habibe KurtDiana O. TreabaJohn L. ReaganAndrew HsuPamela C. EganJames ButeraRabin NiroulaJohn Vatkevich, Jordan Robison, Ilyas Sahin, Allison P. Jacob, Chelsea D. Mullins & Patrycja M. Dubielecka. (2021) Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma. Blood Advances 5:24, pages 5525-5535.
Crossref
Crossref
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, Luca Bertamini, Angelo Belotti, Monica Galli, Massimo Offidani, Elena Zamagni, Antonio Ledda, Mariella Grasso, Stelvio Ballanti, Antonio Spadano, Michele Cea, Francesca Patriarca, Mattia D'Agostino, Andrea Capra, Nicola Giuliani, Paolo de Fabritiis, Sara Aquino, Angelo Palmas, Barbara Gamberi, Renato Zambello, Maria Teresa Petrucci, Paolo Corradini, Michele Cavo & Mario Boccadoro. (2021) Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. The Lancet Oncology 22:12, pages 1705-1720.
Crossref
Crossref
Alexandra E. Kovach, Gordana Raca, Deepa Bhojwani & Brent L. Wood. (2021) Next-Generation Sequencing for Measurable Residual Disease Assessment in Acute Leukemia. Advances in Molecular Pathology 4, pages 49-63.
Crossref
Crossref
Lori A. Ramkissoon & Nathan D. Montgomery. (2021) Applications of next-generation sequencing in hematologic malignancies. Human Immunology 82:11, pages 859-870.
Crossref
Crossref
Marcus H. Hansen, Oriane Cédile, Thomas S. Larsen, Niels Abildgaard & Charlotte G. Nyvold. (2021) Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements—how low can you go?. Experimental Hematology 98, pages 14-24.
Crossref
Crossref
Swetha Kambhampati, Bradley Hunter, Andrei Varnavski, Bita Fakhri, Lawrence Kaplan, Weiyun Z. Ai, Miguel Pampaloni, Chiung-Yu Huang, Thomas MartinIIIIII, Lloyd Damon & Charalambos B. Andreadis. (2021) Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clinical Lymphoma Myeloma and Leukemia 21:4, pages 246-256.e2.
Crossref
Crossref
Yuri Belotti & Chwee Teck Lim. (2021) Microfluidics for Liquid Biopsies: Recent Advances, Current Challenges, and Future Directions. Analytical Chemistry 93:11, pages 4727-4738.
Crossref
Crossref
Peter Juelg, Elena Kipf, Mara Specht, Marion Fillies, Cornelia Eckert, Nils Paust, Roland Zengerle, Michael Lehnert & Tobias Hutzenlaub. (2021) The MRD disk: automated minimal residual disease monitoring by highly sensitive centrifugal microfluidic multiplex qPCR. Lab on a Chip 21:3, pages 558-570.
Crossref
Crossref
A. Sina Booeshaghi, Nathan B. Lubock, Aaron R. Cooper, Scott W. Simpkins, Joshua S. Bloom, Jase Gehring, Laura Luebbert, Sri Kosuri & Lior Pachter. (2020) Reliable and accurate diagnostics from highly multiplexed sequencing assays. Scientific Reports 10:1.
Crossref
Crossref
Dayoung Jung, Preetesh Jain, Yixin Yao & Michael Wang. (2020) Advances in the assessment of minimal residual disease in mantle cell lymphoma. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Travers Ching, Megan E. Duncan, Tera Newman-Eerkes, Mollie M. E. McWhorter, Jeffrey M. Tracy, Michelle S. Steen, Ryan P. Brown, Srivatsa Venkatasubbarao, Nicholas K. Akers, Marissa Vignali, Martin E. Moorhead, Drew Watson, Ryan O. Emerson, Tobias P. Mann, B. Melina Cimler, Pamela L. Swatkowski, Ilan R. Kirsch, Charles Sang, Harlan S. Robins, Bryan Howie & Anna Sherwood. (2020) Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer 20:1.
Crossref
Crossref
Siwen Hu-Lieskovan, Srabani Bhaumik, Kavita Dhodapkar, Jean-Charles J B Grivel, Sumati Gupta, Brent A Hanks, Sylvia Janetzki, Thomas O Kleen, Yoshinobu Koguchi, Amanda W Lund, Cristina Maccalli, Yolanda D Mahnke, Ruslan D Novosiadly, Senthamil R Selvan, Tasha Sims, Yingdong Zhao & Holden T Maecker. (2020) SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. Journal for ImmunoTherapy of Cancer 8:2, pages e000705.
Crossref
Crossref
Steven De Michino, Mansi Aparnathi, Ariana Rostami, Benjamin H. Lok & Scott V. Bratman. (2020) The Utility of Liquid Biopsies in Radiation Oncology. International Journal of Radiation Oncology*Biology*Physics 107:5, pages 873-886.
Crossref
Crossref
Jack Bartram, Bela Patel & Adele K. Fielding. (2020) Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement. Seminars in Hematology 57:3, pages 142-148.
Crossref
Crossref
Iman Abou Dalle, Elias Jabbour & Nicholas J. Short. (2020) Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Therapeutic Advances in Hematology 11, pages 204062072091002.
Crossref
Crossref
Eric Y. Loo. 2020. Follicular Lymphoma and Mantle Cell Lymphoma. Follicular Lymphoma and Mantle Cell Lymphoma
115
148
.
Jacqueline Cloos, Gert J. Ossenkoppele & Richard Dillon. (2019) Minimal residual disease and stem cell transplantation outcomes. Hematology 2019:1, pages 617-625.
Crossref
Crossref